- Home
- MEI vs ZBIO Comparison
MEI vs ZBIO Comparison
Compare MEI & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEI
- ZBIO
- Stock Information
- Founded
- MEI 1946
- ZBIO 2019
- Country
- MEI United States
- ZBIO United States
- Employees
- MEI N/A
- ZBIO N/A
- Industry
- MEI Electrical Products
- ZBIO
- Sector
- MEI Technology
- ZBIO
- Exchange
- MEI Nasdaq
- ZBIO NYSE
- Market Cap
- MEI 464.2M
- ZBIO 389.2M
- IPO Year
- MEI N/A
- ZBIO 2024
- Fundamental
- Price
- MEI $6.54
- ZBIO $8.43
- Analyst Decision
- MEI Buy
- ZBIO Strong Buy
- Analyst Count
- MEI 3
- ZBIO 7
- Target Price
- MEI $11.67
- ZBIO $32.29
- AVG Volume (30 Days)
- MEI 621.2K
- ZBIO 197.8K
- Earning Date
- MEI 03-05-2025
- ZBIO 05-16-2025
- Dividend Yield
- MEI 8.59%
- ZBIO N/A
- EPS Growth
- MEI N/A
- ZBIO N/A
- EPS
- MEI N/A
- ZBIO N/A
- Revenue
- MEI $1,068,300,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- MEI N/A
- ZBIO N/A
- Revenue Next Year
- MEI $5.40
- ZBIO N/A
- P/E Ratio
- MEI N/A
- ZBIO N/A
- Revenue Growth
- MEI N/A
- ZBIO N/A
- 52 Week Low
- MEI $5.84
- ZBIO $5.83
- 52 Week High
- MEI $17.45
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- MEI 33.93
- ZBIO N/A
- Support Level
- MEI $6.21
- ZBIO N/A
- Resistance Level
- MEI $7.02
- ZBIO N/A
- Average True Range (ATR)
- MEI 0.31
- ZBIO 0.00
- MACD
- MEI 0.13
- ZBIO 0.00
- Stochastic Oscillator
- MEI 40.12
- ZBIO 0.00
About MEI Methode Electronics Inc.
Methode Electronics Inc makes component and subsystem devices employing electrical, radio remote control, electronic, wireless, and sensing technologies. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles. The products manufactured in the automotive segment include overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors. Geographically, the company generates maximum revenue from North America and the rest from Europe, the Middle East & Africa (EMEA), and Asia.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.